文献速递产科母胎医学

单胎妊娠早产前胎膜早破孕妇使用孕激素:随机对照试验的系统评价与Meta分析

Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials.
PubMed 文献 · Am J Obstet Gynecol · 2018-03-31

该系统评价与Meta分析检索至2018年1月的6项随机对照试验(n=545),评估孕激素对单胎早产前胎膜早破妊娠的延长孕周作用。17-α羟孕酮己酸酯未延长随机分组至分娩的时间(均数差0.11天,95%CI -3.30至3.53),直肠孕激素亦无差异(均数差4.00天,95%CI -0.72至8.72)。结论为孕激素不延长单胎早产前胎膜早破妊娠。

要点

  • 17-α羟孕酮己酸酯未延长单胎早产前胎膜早破孕妇的潜伏期(均数差0.11天,95%CI -3.30至3.53)。
  • 直肠孕激素未延长潜伏期(均数差4.00天,95%CI -0.72至8.72)。
  • 两组分娩孕周、分娩方式及母儿结局均无差异。

核心结论

  • 孕激素不延长单胎早产前胎膜早破妊娠的孕周。

研究设计与样本

  • 系统评价与Meta分析,检索MEDLINE、OVID、Scopus、EMBASE、ClinicalTrials.gov和Cochrane Central Register of Controlled Trials从建库至2018年1月。
  • 纳入6项随机对照试验,共545例单胎早产前胎膜早破孕妇,随机接受孕激素或对照(安慰剂或不治疗)。
  • 4项试验评估17-α羟孕酮己酸酯,1项评估直肠孕激素,1项三臂试验比较17-α羟孕酮己酸酯、直肠孕激素和安慰剂。
  • 采用DerSimonian and Laird随机效应模型计算相对危险度及95%置信区间,按孕激素给药途径分别分析。
  • 排除有期待治疗禁忌(绒毛膜羊膜炎、重度子痫前期、胎儿状态不可靠)及多胎妊娠的试验。

主要发现

  • 17-α羟孕酮己酸酯组随机分组时平均孕周26.9周,对照组27.3周。
  • 17-α羟孕酮己酸酯未延长随机分组至分娩的潜伏期(均数差0.11天,95%CI -3.30至3.53)。
  • 直肠孕激素未延长潜伏期(均数差4.00天,95%CI -0.72至8.72)。
  • 两组分娩平均孕周、分娩方式及母儿结局均无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE DATA: Preterm prelabor rupture of membranes occurs in 3% of all pregnancies. Neonatal benefit is seen in uninfected women who do not deliver immediately after preterm prelabor rupture of membranes. The purpose of this study was to evaluate whether the administration of progestogens in singleton pregnancies prolongs pregnancy after preterm prelabor rupture of membranes. STUDY: Searches were performed in MEDLINE, OVID, Scopus, EMBASE, ClinicalTrials.gov, and the Cochrane Central Register of Controlled Trials with the use of a combination of keywords and text words related to "progesterone," "progestogen," "prematurity," and "preterm premature rupture of membranes" from the inception of the databases until January 2018. We included all randomized controlled trials of singleton gestations after preterm prelabor rupture of membranes that were randomized to either progestogens or control (either placebo or no treatment). Exclusion criteria were trials that included women who had contraindications to expectant management after preterm prelabor rupture of membranes (ie, chorioamnionitis, severe preeclampsia, and nonreassuring fetal status) and trials on multiple gestations. We planned to include all progestogens, including but not limited to 17-α hydroxyprogesterone caproate, and natural progesterone. STUDY APPRAISAL AND SYNTHESIS METHODS: The primary outcome was latency from randomization to delivery. Metaanalysis was performed with the use of the random effects model of DerSimonian and Laird to produce relative risk with 95% confidence interval. Analysis was performed for each mode of progestogen administration separately. RESULTS: Six randomized controlled trials (n=545 participants) were included. Four of the included trials assessed the efficacy of 17-α hydroxyprogesterone caproate; 1 trial assessed rectal progestogen, and 1 trial had 3 arms that compared 17-α hydroxyprogesterone caproate, rectal progestogen, and placebo. The mean gestational age at time randomization was 26.9 weeks in the 17-α hydroxyprogesterone caproate group and 27.3 weeks in the control group. 17-α Hydroxyprogesterone caproate administration was not found to prolong the latency period between randomization and delivery (mean difference, 0.11 days; 95% confidence interval, -3.30 to 3.53). There were no differences in mean gestational age at delivery, mode of delivery, or maternal or neonatal outcomes between the 2 groups. Similarly, there was no difference in latency for those women who received rectal progesterone (mean difference, 4.00 days; 95% confidence interval, -0.72 to 8.72). CONCLUSION: Progestogen administration does not prolong pregnancy in singleton gestations with preterm prelabor rupture of membranes.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Quist-Nelson J, Parker P, Mokhtari N, et al. Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials. Am J Obstet Gynecol. 2018. PMID: 29614278. doi:10.1016/j.ajog.2018.03.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。